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Abstract
One hypothesis to account for MHC-restriction by T cell receptors (TCRs) holds that there are
several evolutionary-conserved residues in TCR variable regions that contact MHC. While this
‘germline-codon’ hypothesis is supported by various lines of evidence, it has been difficult to test.
The difficulty stems in part from the fact that TCRs exhibit low affinities for pep/MHC, thus
limiting the range of binding energies that can be assigned to these key interactions using
mutational analyses. To measure the magnitude of binding energies involved, here we used high-
affinity TCRs engineered by mutagenesis of CDR3. The TCRs included a high-affinity, MART-1/
HLA-A2-specific single-chain TCR and two other high-affinity TCRs that all contain the same Vα
(HLA-A2), with different peptides and Vβ regions. Mutational analysis of residues in CDR1 and
CDR2 of the three Vα2 regions showed the importance of the key ‘germline codon” residue Y51.
However, two other proposed key residues showed significant differences among the TCRs in
their relative contributions to binding. Using single-position, yeast-display libraries in two of the
key residues, MART-1/HLA-A2 selections also revealed strong preferences for wild-type
‘germline codon’ residues, but several alternative residues could also accommodate binding and
hence, MHC-restriction. Thus, although a single residue (Y51) could account for a proportion of
the energy associated with positive selection (i.e. MHC-restriction), there is significant plasticity
in requirements for particular side-chains in CDR1 and CDR2 and in their relative binding
contributions among different TCRs.
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T cell-mediated recognition of a foreign peptide bound to a product of the major
histocompatibility complex (MHC) occurs through the αβ T-cell receptor (TCR), in a
process that is referred to as MHC-restriction. TCRs contain six complementarity
determining regions (CDR), three (CDR1, 2, and 3) in each α and β chain. CDR1 and 2
loops are “germline derived” since they reside in the region encoded by each variable region
gene, which do not undergo either somatic mutation or rearrangements. CDR3 loops are
more variable in sequence as they are encoded by the junctions of somatically rearranged
gene segments (VJ in the α locus, and VDJ in the β locus), similar to antibodies.
In virtually all of the structures of TCR:pep/MHC complexes, the CDR1 and 2 loops are
found to dock over the helices of the MHC protein, whereas the CDR3 loops are positioned
over the peptide where they can contribute most importantly to the antigen specificity of the
reaction1; 2. Despite these generalizations, there are cases where CDR1 residues are near the
peptide and CDR3 residues appear to contact the MHC protein3–6.
While there is conserved, diagonal docking of TCRs over pep/MHC ligands, the
complexities associated with the diversity of TCRs, peptides, and MHC proteins have made
it difficult to reveal conserved chemistries of the interactions that could account for the
process of MHC restriction. More recent evidence, where the structures of TCRs with the
same V regions and the same MHC restricting elements have been compared, has led to the
“germline codon” hypothesis. In this hypothesis, several key residues in CDR1 and/or
CDR2 interact invariably with residues from the MHC protein, suggesting that these TCR
residues evolved to establish the biochemical basis of MHC-restriction. Results of
mutagenesis of these residues have been consistent with their contribution to binding7–11, or
even in the process of positive selection12. However, these studies have been unable to
reveal the energetic importance of the residues among different TCRs.
A recent study suggested that there is no absolute requirement for specific residues within
the germline Vα or Vβ loops, as it was possible to modify these very significantly and still
achieve MHC-restriction and positive selection in the thymus13. Whether these modified
TCRs retained the diagonal footprint characteristic of conventional TCRs remains to be
seen. Another study showed that the CDR3 regions can significantly alter the germline-
encoded interactions14.
Studies with the mouse 2C system showed that two of the predicted “germline codon”
residues in CDR2β (Y46 and Y48) were unable to bind the SIY/Kb antigen when the
residues were changed to alanines7; 15. More recent work with a high-affinity mutant of the
mouse 2C (m33), generated in CDR3α, showed that the TCR docked in an identical way as
the wild-type TCR, and that all of the CDR1 and CDR2 contacts were preserved16; 17. In
addition, both the 2C TCR and the m33 TCR had the same amino acid preferences at Y46,
using a T-cell library based approach18. To the best of our knowledge, there have not been
studies with human TCR single-site mutants to understand the issue of CDR1 and CDR2
contributions to binding properties, in large part because wild-type affinities are already so
low. This prompted us to more fully exploit the idea of using high-affinity TCRs to
determine the requirements and binding energies associated with MHC restriction in a
human system.
Recently, we described the engineering of two human single-chain TCRs, 868 and A6, with
high-affinity for HLA-A2-restricted peptides HIV (SL9 or Gag) and Tax, respectively19.
This study showed that the Vα2 (IMGT:TRAV12) region was stable compared to other V
regions, and that a polymorphism in framework residue 49 of Vα2 facilitated the display,
engineering, and expression of soluble scTv fragments in E. coli. Using this as a platform
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for work with additional human TCRs, here we have engineered a third Vα2-containing
scTv against the MART- 1/Melan-A peptide restricted by HLA-A2; MART-1 is a human
differentiation antigen expressed in more than 80% of metastatic melanoma tumors20.
Collectively, these three TCRs, with the same CDR1α and CDR2α, provided an opportunity
to examine the energetic impact of several key residues. In addition, there are several
published crystal structures of Vα2-containing TCR:pep-HLA-A2 complexes3–5; 21,
including the A6 TCR, providing a structural framework for the interpretation of the results.
Using a combination of alanine-scanning mutagenesis, and library-based selections with
pep/HLA-A2, our findings indicated that: 1) two of the proposed CDR1 germline codon
residues, R28 and Q31, contributed to binding in some cases, but not in others, consistent
with recent structural studies suggesting that CDR3 editing can influence CDR1 contacts14,
2) one of the germline codon residues, Y51, exhibited similar and significant contributions
to binding in all three cases (~1.5–2 Kcal/mol in free energy); the free energy contributions
of this residue, together with that contributed by one of the CDR1 residues, would be
sufficient to produce an equilibrium binding constant (KD value ~ 1 mM; ΔG ~ 4 Kcal/mol)
associated with co-receptor dependent positive selection; and 3) using a library approach,
the tyrosine at position 51 was preferred for pep-HLA-A2 binding, relative to almost all
other amino acids, although several conserved side chains (Phe, Trp) could be substituted.
Thus, there is plasticity in the binding requirements of the germline encoded residues, but
the evidence suggest that there has been evolutionary pressure to maintain certain key
residues.
Results
Affinity-engineering a human TCR against MART-1/HLA-A2
The Vα2-positive MART-1-reactive T cell clone, INRi-T1 (referred to as T1), was isolated
from a melanoma-reactive T-cell line. In order to engineer a receptor with improved binding
affinity, the V regions were cloned as a single-chain TCR fragment (scTv) in the orientation
Vβ-linker-Vα into a yeast-display vector. The scTv was expressed on the surface of yeast
via an N-terminal Aga2 fusion followed by a hemagglutinin (HA) epitope tag for detection
of the displayed protein (Fig. 1A). Additionally, a F49S mutation was introduced into the
Vα2-domain of the construct to confer thermal stability to the scTv, as described
previously19.
Induced yeast cells containing the T1 scTv fusion (template) were positive with an anti- HA
epitope antibody (Fig. 1B). In order to detect individual Vα and Vβ domains, anti-Vα2 and
anti-Vβ16 monoclonal antibodies were used for staining. Positive staining was seen with the
anti-Vα2 antibody and weak staining was observed with the anti-Vβ16 antibody.
Temperature stability assays have suggested that the Vβ16 antibody recognizes a
conformational epitope whereas the Vα2 antibody recognizes a linear epitope (data not
shown). This suggested that most of the T1 scTv fragments were not properly folded on the
surface of yeast.
To generate a more stable T1 scTv that would be expressed on the surface of yeast, we
performed random mutagenesis and selected for clones with improved surface expression by
binding to the anti-Vβ16 antibody. Previous work with mouse TCRs 2C and 3L.2 and
human TCRs A6 and 868 have shown that selection of scTvs with enhanced yeast surface
expression and temperature stability also correlate with increased soluble
expression19; 22; 23. Following two rounds of sorting, several mutants that had improved
binding to the anti-Vβ16 antibody were isolated. Clones were screened for resistance to
thermal denaturation using the Vβ16 as a probe (data not shown), and the scTv mutant T1-
S18 was selected for use as a template for affinity engineering (Fig. 1B, middle panels). The
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T1-S18 scTv was sequenced and shown to contain four mutations: two in the Vα (S40P and
Q80R), one in the Vβ (V80I), and one in the linker (K8E)(Supplementary Fig. 1).
Engineering of a high affinity surface displayed T1 scTv fragment via site directed
mutagenesis
Degenerate libraries were made in the CDR3 loops in order to select for mutants for
increased affinity to peptide MART-1/HLA-A2/Ig dimers. CDR3 libraries of the T1-S18
template were sorted with two variants of the MART-1 peptide: the nonamer spanning
residues 27–35 (AAGIGILTV) and decamer spanning residues 26–35 which contained a
modified anchor residue at position 2 (ELAGIGILTV). Some MART-1-specific TCRs have
been shown to crossreact with nonamer, decamer, and anchor-modified decamer
peptides24–27. After four rounds of selection by FACS with MART-1/HLA-A2/Ig dimers,
various clones were isolated and examined for binding. Clone T1-S18.45, isolated with
MART-1 (ELAGIGILTV)/HLA-A2, showed significant binding, whereas the template T1-
S18 and wild-type T1 did not (Fig. 1B). Clone T1-S18.45 also showed the greatest binding
improvement to the 9mer variant of the MART-1 peptide (AAGIGILTV) on the surface of
yeast, despite isolation with the anchor-modified 10mer peptide (data not shown).
Sequencing revealed that T1-S18.45 contained five mutations in CDR3α, from wild-type
NDNAR to SSSDF (Supplementary Fig. 1).
Expression and binding studies of soluble T1 single-chain TCRs
The T1, T1-S18, and T1-S18.45 scTv genes (Vβ-linker-Vα) were cloned into an E. coli
expression vector, induced to express the recombinant scTv, and refolded from inclusion
bodies. Refolded preparations were purified by Ni-affinity and size exclusion
chromatography, yielding scTv proteins of the expected monomeric molecular weight, 30
kDa (Fig. 2A). Surface plasmon resonance (SPR) was performed with immobilized scTv
fragments to determine kinetics and binding affinities for the various MART-1 peptide
variants. Kinetic titrations were performed in order to avoid regeneration steps. SPR data
analysis revealed nanomolar affinities of T1-S18.45 for all three MART-1 peptide variants
examined (Fig. 2B and 2C). The stabilized T1-S18 variant bound with micromolar affinities,
yielding affinity improvements of the T1-S18.45 scTv of 700 to 4,500-fold for the
ELAGIGILTV, ALGIGILTV, AAGIGILTV peptide complexes, respectively (Fig. 2C). The
wild-type scTv T1 did not exhibit detectable binding, perhaps because it lacked adequate
stability for immobilization and analysis. The micromolar affinities of the T1-S18, non-
affinity matured TCR are in the same range as typically seen for most pep/MHC antigens.
To study whether the high-affinity, soluble scTv T1-S18.45 protein could detect
peptide:HLA-A2 complexes on the surface of antigen presenting cells, the protein was
biotinylated utilizing a biotin-succinimidyl cross-linking agent28. MART-1 (ELAGIGILTV)
or null SL9 (SLYNTVATL) peptides were incubated with the TAP-deficient, HLA-A2+
human cell line T2. Following peptide pulsing, T2 cells were stained with various
concentrations of T1-S18.45- biotin followed by SA-PE, and analyzed by flow cytometry
(Fig. 3). Specific staining for MART-1 was observed, yielding an estimated EC50 affinity
measurement of 120 nM, similar to that observed by SPR.
Alanine scanning mutagenesis of Vα2-containing high affinity scTv fragments
The availability of three Vα2+ TCRs with high-affinity (called A6, 868, and T1 here), each
for a different peptide:HLA-A2 ligand, allowed us to compare the exact binding contribution
of proposed key CDR1 and CDR2 residues among different TCRs. To examine the binding
energetics of these peptide/MHC interactions, alanine mutants were generated at five
positions in a panel of high affinity Vα2-containing scTv proteins: CDR1α residues D27,
R28 and Q31, and CDR2α residues Y51 and S52. These residues have shown conservation
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based on TCR sequence alignments29 and the R28, Q31, Y51, and S52 side chains appear to
be involved in contacts with the HLA-A2 helices in structures of three Vα2-containing
TCRs (A6, Mel5, and DMF5; PDB files 1AO7, 3HG1, and 3QDG)(Fig. 4)3–5. Position D27
in CDR1α was the target of mutation for computationally-guided affinity increases in two
Vα2-containing TCRs, A6 and DMF530; 31, and thus was also included in our analysis.
The yeast display system allows direct titrations of the fusion protein in order to examine
affinities above a threshold KD of about 1 µM, thereby avoiding the need to purify each
protein or mutant32. Accordingly, each alanine mutant was titrated with various
concentrations of cognate peptide:HLA-A2 and analyzed by flow cytometry (Fig. 5A,B,C).
To compare mutants, the magnitude of changes in binding affinity were calculated from the
concentrations of ligand that resulted in half-maximal binding of alanine mutant compared
to ‘wild-type’ high-affinity scTv (Fig. 5D). For all three scTv fragments, the tyrosine at
position 51 was the only residue that uniformly contributed significant binding (10 to ≥15-
fold reductions in binding affinity of the alanine mutants) to the peptide:HLA-A2
interaction, regardless of the Vβ or the peptide. Other positions showed minimal effects for
all three TCRs (R28A and S52A), an effect on only one TCR (D27A in the A6 TCR), or an
effect on two TCRs (Q31A in the A6 and 868 TCRs). Thus, these positions showed
plasticity in their contribution to the binding energy.
In order to determine if the effect of the Y51A mutation observed in the high affinity T1,
A6, and 868 scTv fragments would hold true for the wild-type TCRs, variants of each scTv
that contained the wild-type CDR loops, with or without the corresponding Y51A mutation,
were cloned and expressed in E. coli (note that the affinities of wild-type scTv fragments are
too low to detect binding in the yeast display format). The 868 scTv fragment and its Y51A
mutant were unstable and could not be used to make reliable SPR measurements. However
we were able to measure steady state equilibrium binding parameters for wild-type T1 and
A6 single-chain TCRs and their Y51A mutants (stabilized versions of these scTv, without
the affinity mutations). These binding measurements yielded a ΔΔG value of over −2 kcal/
mol for Y51A of the T1 scTCR (i.e. KD of 22 µM for the wild-type, whereas binding by the
Y51A mutant could not be detected; hence, we estimated a KD value of greater than 1 mM
for the Y51A mutant). A ΔΔG value of - 0.8 kcal/mol for Y51A of the A6 scTCR was
measured (KD values of 2.2 µM and 10 µM for wild-type and Y51A, respectively).
Additionally, a recent study by Piepenbrink and colleagues showed that the Y51A mutation
in the wild-type full-length A6 TCR yielded a ΔΔG value of −0.6 kcal/mol mol, similar to
that of the Vα2-containing DMF5 TCR33. Thus, we conclude that tyrosine 51 in the CDR2
of Vα2 contributes to binding energy among different TCRs in both the affinity-matured
TCRs and the wild-type affinity TCRs.
Peptide:HLA-A2 selections from single-residue libraries of the MART-1 TCR
If during evolution the key CDR1 and CDR2 residues have been selected for MHC-binding,
then peptide/MHC sorting of a yeast display library of all amino acids at these positions
should yield enrichment for the evolutionary-driven residues. In order to determine the
allowable residues at key positions of MHC restrictions, degenerate libraries (NNS codons)
at Vα positions 31 and 51 positions were generated in the T1-S18.45 scTv yeast display
vector. Each library underwent one round of selection with 45 nM MART-1/HLA-A2, and
the top 8–10% binding clones were isolated by sorting. DNA from the enriched population
of yeast was then subjected to 454 high-throughput sequencing to determine the amino acid
frequency selected at each position (Fig. 5). At position 31, the wild-type glutamine was the
highest frequency isolate, followed by alanine, cysteine, and valine (Fig. 5A). At position
51, tyrosine (wild-type), phenyalanine, and tryptophan were the highest frequency isolates
(Fig. 5B). Thus, each positional library demonstrated a preference for the wild-type,
energetically important residue, consistent with an evolutionary pressure to maintain these
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residues. However, several other amino acids were also capable of supporting peptide/MHC
binding.
Discussion
Crystal structures of different TCR:pep/MHC complexes have shown a conserved docking
mode of TCR on the peptide/MHC such that the CDR1 and 2 loops are approximately
positioned over the MHC helices and CDR3 over the peptide1; 2; 29. Evidence for the co-
evolution of these molecules has been shown by the presence of conserved residues and
interactions in specific positions in CDR1 and 2 loops29. In the current study we focused on
the energetic contribution of putative conserved TCR residues that shape immune
recognition.
During development in the thymus, T cells are required to bind to MHC within a narrow
affinity range in order to pass both positive and negative selection. Mutagenesis studies have
shown that single residue differences in CDR1 and 2 loops are able to shift T cells out of
this affinity such that negative selection or death by neglect can occur12; 29. Although the
TCR’s intrinsic reactivity towards MHC could be partially masked by the negative selection
process, structural and sequence data have suggested putative conserved residues that may
play an important role in the binding energetics of the TCR:pep/MHC interface.
Higher affinity single-chain TCRs provide an approach to rapidly assess alanine mutants
using yeast display and flow cytometry without the need to express large quantities of
protein as has been done in previous studies7–11; 34; 35. Use of the higher affinity scTvs
allows for detection of up to 100-fold decreases in affinity that would not otherwise be
measurable within the normal range for TCR:pep/MHC (1–100 µM)2. Thus far, mutations
that confer higher affinity on the variants of TCRs have most often been engineered in the
CDR3 loops, in order to retain peptide specificity19; 23; 36–41. CDR1 loops often contact the
MHC helices, and CDR2 loops tend to almost exclusively contact the MHC helices, and
thus wild-type residues in these loops provide a good framework to access the binding
energetics of “germline-encoded” contacts on HLA-A2 by alanine scanning mutagenesis.
Furthermore, the structures of several high-affinity mouse TCRs in CDR3 residues have
shown virtually identical CDR1 and CDR2 contacts with MHC as the wild-type TCR16; 17.
Thus, we believe that the high-affinity TCRs provide a useful surrogate for these wild-type,
germline encode residues in CDR1 and CDR2.
Our data showed that the putative conserved CDR2α residue Y51 contributed substantially
to binding in all three of the high-affinity scTv fragments examined. Although tyrosine at
this position is not abundant (in 12–16% of Vα regions), it interacts with the same region of
MHC class I (near residue Q155) and class II (near βA73) in various structures29. Structural
analysis of three Vα2-containing TCRs, A65, Mel54, and DMF53, suggest that the binding
energy associated with mutation of Y51 to alanine could be due to the loss of contacts with
HLA-A2α2 helix position(s) E154, Q155, and/or A158 (Fig. 4). In all three high-affinity
scTv fragments examined, mutation to alanine led to a 10 to ≥15-fold decrease in binding
affinity (≥1.4 kcal/mol in free energy).
While measurement of these interactions took advantage of the ability to use yeast display to
rapidly analyze binding by the higher affinity variants, we were able to confirm the energetic
role of the tyrosine at position 51 in wild-type scTv variants in which all CDR affinity
mutations were reverted to the wild-type residues. These results are consistent with the
similar docking and chemistries associated with wild-type TCR and affinity-matured TCRs
in the 2C system, showing only the CDR3 loop with mutations in a different position 16; 17.
Although qualitatively we show that Y51 contributed to binding in both high-affinity and
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wild-type TCRs, structural studies will be required to determine if there are changes in the
docking of each of the loops and their residues. In this regard, a recent comparison of the A6
TCR/Tax/HLA-A2 complex with the high-affinity mutant A6-c134 TCR/Tax/HLA-A2
complex showed that the docking orientations were virtually identical21. While there were
subtle changes in the positions the CDR3 and CDR2β loops, the positions of the CDR1α and
CDR2α, and in particular the position of the side chain of Y51, were very similar
(Supplemental Figure 2). In their report, the authors proposed that most of the increase in
binding affinity of the A6-c134 TCR was achieved through a greater number of interactions
between the CDR3 loops and the peptide.
As positive selection is associated with weak affinities and free energies in the range of ~4
kcal/mol42, the contributions by this conserved tyrosine could reflect a substantial portion of
this “minimal” affinity to ensure representation in the T cell repertoire. Early studies in the
2C system showed that affinities as low as 300 µM were able to yield agonist activity43.
Additionally we have shown that a single peptide point substitution, F5R, in the peptide of
the 2C TCR:QL9- Ld interaction reduced the affinity of the 2C TCR from 1.6 µM to 300
µM, yet the interaction was sufficient for agonist activity44. Based on this, it is reasonable to
assume that an affinity of 1 mM (~4 kcal mol−1) or even lower (higher KD value) is likely to
be in the range for positive selection.
Although binding analysis showed a consistent role of CDR2α residue Y51, more plasticity
was observed in the contribution of CDR1α residues. For example, the D27A mutation led
to a >15-fold decrease in binding of Tax/A2 by the A6 X15 TCR but this same mutation did
not have a significant impact on binding by the other TCRs. The effect of the D27A
mutation in the A6 TCR could be indirect, perhaps influencing the adjacent R28 through
electrostatic interactions and affecting the stability of the entire loop. Similarily, the Q31A
mutation caused a >15-fold change in both A6-X15 and T1-S18.45 TCRs, but the 868-Z11
TCR was not significantly affected. It has been proposed that CDR3 loops are able to
modulate interactions of the MHC with germline derived CDR1 and 2 loops in a process
termed ‘CDR editing’14. This may account for the variation in binding contribution of
residues in CDR1α. Analysis of contacts in crystal structure of Vα-containing TCRs DMF4,
DMF5, A6, and Mel5 suggest a role of CDR1α in making peptide contacts in addition to
MHC contacts3; 4, which may also explain differences in the energetic contribution with
different peptide ligands.
In order to further understand the requirements for binding, single codon yeast display
libraries were generated at the two most energetically important CDR1 and CDR2 residues
of the high-affinity T1-S18.45 TCR. The preferential selection of aromatic amino acids at
position 51 (i.e. wild-type Tyr, Phe, and Trp) further supports the conservation at this
position, and may reflect a general requirement for bulky amino acids which can adapt to
varying MHC structures or chemistry45. However, position 31 showed a more diverse
collection of allowable amino acids, from the chemical perspective, at this position (i.e.
wild-type Gln, Cys, Ala, and Val). Nevertheless, the preferences for the wild-type residues
in each case are consistent with their evolutionary pressures to retain these in the context of
the Vα2:HLA-A2 interaction. This is not to say, however, that other CDR loops or residues
would not suffice to provide the very low energy of interaction required for MHC-restriction
through positive selection13. Clearly, the maintenance of the docking angle and general
positions of each CDR loop in all wild-type TCRs and their high-affinity TCR counterparts
suggests that the MHC interactions with CDR1 and CDR2 could collectively be capable of
restraining the orientation of the complex, even in the absence of co-receptor (since the
high-affinity TCRs described here were selected in the absence of CD8).
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In a recent study comparing the crystal structures of G4 and E4 TCRs with their cognate
ligand mutTPI-DR1, Mariuzza and coworkers showed that CDR2α made identical contacts
with the MHC helices in both structures, but there was more plasticity or “wobble” in
CDR1α loops, a finding that they attribute to the influence of the CDR314. Our study
provides a corresponding binding energy analysis that is consistent with these structural
findings. Furthermore, we suggest that the energetically-conserved CDR2α residue (Y51)
provides sufficient binding energy to contribute significantly to the very low affinity
interactions required for positive selection. Although our study does not examine the
importance of TCRβ chain residues or the impact of the co-receptor, crystal structures of the
A6 TCR have suggested that the TCRα chain may dominate in the interaction with Tax/
A25; 46–48. The structures of the other two Vα2-positive TCRs described here are not known
so it remains to be seen if their Vβ CDR1 and CDR2 play a more significant role than the
A6 TCR.
Materials and methods
Antibodies, peptide:HLA-A2, and Flow Cytometry
Antibodies used to detect yeast surface expression included: anti-HA eptiope tag (Clone HA.
11; Covance), anti-Vβ16 antibody (Clone TAMAYA1.2; Beckman-Coulter), anti-Vα2
monoclonal antibody generated in our laboratory (data not shown), Goat-anti-mouse IgG
F(ab’)2 AlexaFluor 647 secondary antibody (Invitrogen), and Streptavidin-phycoerythrin
(SA:PE, BD Pharmingen). Peptides that bind to HLA-A2 [Tax11 – 19: LLFGYPVYV,
SL977 – 85 (HIV-Gag): SLYNTVATL, MART-126 – 35 A27L: ELAGIGILTV,
MART-127 – 35: AAGIGILTV27, and MART-127–35 A28L: ALGIGILTV] were synthesized
by standard F-moc (N-(9-fluorenyl)methoxycarbonyl) chemistry at the Macromolecular
Core Facility at Penn State University College of Medicine (Hershey, PA, USA). For FACS
and flow cytometry analysis, recombinant soluble dimeric HLA-A2:Ig fusion protein (BD
DimerX) was used. Additionally, a monomeric HLA-A2-biotin reagent generated by the
exchange of a UV-cleavable peptide for another HLA-A2-restricted peptide in the presence
of UV light was utilized to determine fold changes of binding in alanine mutants on the
surface of yeast cells49; 50.
Cloning and expression of scTv in yeast display vectors
TCR variable region fragments (scTv) were expressed in yeast display plasmid pCT302
(Vβ-L-Vα)51, which contains a galactose-inducable AGA2 fusion allowing for growth in
Trp media. Induction of the scTv gene involves growth of the transformed EBY100 yeast
cells to stationary phase in selection media followed by transfer to galactose-containing
media. The T1 single-chain gene for TCRs was synthesized by Genscript (Piscataway, NJ,
USA) with a F49S mutation in the Vα2-domain of the construct19.
The MART-1-specific TCR genes were isolated from CTLs obtained by the MART- 1/
HLA-A2 multimer-guided cloning as previously described52. The T1 scTv consisted of the
variable contains attached by the linker region GSADDAKKDAAKKDGKS19; 23; 53. The
scTv was introduced into the NheI and XhoI restrictions sites of pCT302 (Sequences in
Supplementary Fig. 1).
Generation, display, and selection of mutated scTv yeast display libraries
Error-prone PCR was used to generate random mutations, as previously described54. CDR3
libraries were generated using Splicing by overlap extension (SOE) PCR spanning 5
adjacent codons at a time (2 libraries in each CDR3 loop)55. Pre-SOE PCR products were
generated for each of the four libraries utilizing the following primer pairs. β1: 5'- GGC
AGC CCC ATA AAC ACA CAG TAT -3' (Splice 4L) and 5'- TGA AGA GGC GCA AAA
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ATA CAC ACC AGA ATC TTC CAG TTC GGC CGG TTG AAT TTT CAG GG -3', and
5'- GGA AGA TTC TGG TGT GTA TTT TTG CGC CTC TTC ANN SNN SNN SNN SNN
SGT TGA ACA GTA TTT TGG TCC AGG TAC CCG TC -3' and 5'- TAA TAC GAC
TCA CTA TAG GG -3' (T7); β2: Splice 4L and 5'- TGA AGA GGC GCA AAA ATA CAC
ACC AGA ATC TTC CAG TTC GGC CGG TTG AAT TTT CAG GG -3', and 5'- GGA
AGA TTC TGG TGT GTA TTT TTG CGC CTC TTC ACA TGC GGG TCT GNN SNN
SNN SNN SNN STT TGG TCC AGG TAC CCG TCT GAC C -3' and T7; α1: Splice 4L
and 5'- CAC CGC GCA CAG ATA AGT GGC TGA ATC AGA TGG TCG AGA ATC
TCT AAT CAG CAG TGA AAC ATA CTG AGA -3', and 5'- CCA TCT GAT TCA GCC
ACT TAT CTG TGC GCG GTG NNS NNS NNS NNS NNS CTG ATG TTT GGC GAT
GGT ACC CAG CTG GTT GTG -3' and T7; α2: Splice 4L and 5'- CAC CGC GCA CAG
ATA AGT GGC TGA ATC AGA TGG TCG AGA ATC TCT AAT CAG CAG TGA AAC
ATA CTG AGA -3', and 5'- CCA TCT GAT TCA GCC ACT TAT CTG TGC GCG GTG
AAT GAT NNS NNS NNS NNS NNS TTT GGC GAT GGT ACC CAG CTG GTT GTG
-3' and T7. SOE PCR was performed with each corresponding Pre-SOE along with both T7
and Splice 4L for each library.
Yeast libraries were made by homologous recombination in EBY100 yeast by
electroporating error prone or SOE PCR products along with NheI and XhoI digested
pCT30255. The library was induced in galactose-containing media (SG-CAA) for 48 h,
washed with 1 mL 1% PBS/BSA, and stained with the following: anti-HA eptiope tag
(1:50), anti-Vα2 antibody (1:50), anti-Vβ16 antibody (1:50) along with goat-anti-mouse IgG
F(ab’)2 AlexaFluor 647 secondary antibody (1:100), and corresponding peptide/HLA-A2
DimerX (100 nM) followed by SA-PE (1:100). Cells were washed (1 ml, 1% PBS/BSA),
and the most fluorescent cells were selected using a FACS Aria (BD Bioscience) high-speed
sorter. Selection was performed on the error prone library for anti-Vβ16 antibody staining
(1:50). In order to test thermal stability of isolated clones, yeast were incubated at elevated
temperature for 30 min prior to the staining protocol. Each individual CDR library was
sorted for positive Vβ16-staining, pooled in equal cell numbers, and expanded. CDR3
library was selected with MART-1/HLA-A2 dimer (10–100 nM).
Expression in E. coli, refolding, and biotinylation of soluble scTv fragments
T1 wild-type, T1-S18, and T1-S18.45 were introduced into the pET28a expression vector
with a N-terminal 6-His tag using NcoI and EcoRI restriction sites (forward primer: 5’ TAT
ACC ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG
CCG CGC GGC AGC GAA GCT GGT GTT ACT CAA TTC 3’, Reverse primer: 5’ T TTA
GAA TTC TTA AAT ATT CGG TTT CAC AAC CAG 3’). Plasmids were transformed into
the BL21 cell line, expanded, and induced for expression. Following induction, cells were
passed through a microfluidizer (Microfluidics Corporation, Newton, MA, USA), inclusion
bodies were isolated, and protein was purified as previously described56. Soluble scTv were
refolded and purified with Ni agarose resin (Qiagen, Valencia, CA) followed by gel
filtration (Superdex 200). Folded scTvs were biotinylated using N-hydroxysuccinimide
(NHS) biotin ester (EZ-Link Sulfo-NHS-LC-Biotin Kit, Pierce/Thermo Scientific).
Biotinylation was verified by gel-shift with streptavidin by SDS– PAGE.
Binding of scTv proteins measured by surface plasmon resonance
The binding of purified refolded scTv proteins to cognate peptide/HLA-A2 was monitored
with surface plasmon resonance (SPR) using a Biacore 3000 instrument. Peptide/HLA-A2
were generated by refolding from bacterially expressed heavy chain and β2m inclusion
bodies as previously described57. Due to the high affinities of the scTv proteins, a kinetic
titration assay was utilized, in which increasing concentrations of analyte were sequentially
injected over the surface without the requirement for disruptive regeneration injections58.
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Experiments were performed with Τ1 wild-type (not detectable), T1-S18, and T1-S18.45-
amine coupled to a standard CM5 sensor chip. Peptide/MHC analyte was sequentially
injected at various concentrations. The amount of immobilized scTv was kept below 500 RU
and the flow rate was set to the maximum of 100 ml/min to minimize mass transport effects.
Data were analyzed using Biaevaluation 4.1 as described58. Solution conditions were 10
mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P-20, 258C.
Binding of scTv fragments to peptide-pulsed antigen presenting cells
HLA-A2+ human cell line, T2 was incubated at 37 degrees for 2–3 hours with 1 µM
MART-1 (ELAGIGILTV) or null SL9 (SLYNTVATL) peptide. Cells were then washed
twice with 1% PBS/BSA, and incubated on ice for 1 hour with biotinylated scTv at various
concentrations. Cells were washed twice with 1% PBS/BSA, followed by incubation with
SA:PE for 30–45 min on ice. Cells were washed twice and analyzed using an Accuri C6
Flow Cytometer. Experiments were done with n=4.
Alanine scanning mutagenesis of scTvs
Four site-directed alanine mutants (CDR1α D27A, R28A and Q31A, and CDR2α Y51A and
S52A) were introduced into previously described high affinity scTvs, A6 X15 and 868
Z1119, and T1-S18.45 by site-directed mutagenesis using a Quikchange kit (Stratagene, La
Jolla, CA). Yeast cells displaying the single-site mutants were titrated with cognate-peptide
exchanged HLA-A2 monomers in triplicate at 8 nM, 40 nM, 200 nM, 1 µM, and 5 µM and
analyzed by flow cytometry49; 50. Values were normalized using nonlinear regression
analysis. Changes in binding affinity were approximated by determining the scTv
concentrations at one-half maximal wild-type binding (5 µM). Independent experiments
were performed with peptide/HLA-A2 dimers (BD DimerX) with similar results (data not
shown).
Yeast display library generation, selection, and 454 sequencing of scTv libraries
Two libraries were generated in the high affinity T1-S18.45 scTv construct at CDR1α
residue Q31 and CDR2α residue Y51 using SOE PCR as described above. Each library was
stained with 45 nM MART-1 (ELAGIGITV)/HLA-A2 and sorted via FACS. Top staining
(8–10%) clones were isolated, and amino acid sequences were determined by 454
sequencing (Roche/454 GS FLX+ Sequencer).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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scTv Single-chain T cell variable fragment
scFv Single-chain variable fragment
SPR Surface plasmon resonance
T1 InRi-T1 T cell clone
TCR T cell receptor
Vα/Vβ Variable chain alpha / variable chain beta
References
1. Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is
surprisingly simple. Nature Immunol. 2009; 10:143–147. [PubMed: 19148199]
2. Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu.
Rev. Immunol. 2006; 24:419–466. [PubMed: 16551255]
3. Borbulevych OY, Santhanagopolan SM, Hossain M, Baker BM. TCRs used in cancer gene therapy
cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms. J. Immunol. 2011;
187:2453–2463. [PubMed: 21795600]
4. Cole DK, Yuan F, Rizkallah PJ, Miles JJ, Gostick E, Price DA, Gao GF, Jakobsen BK, Sewell AK.
Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.
J. Biol. Chem. 2009; 284:27281–27289. [PubMed: 19605354]
5. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between
human T-cell receptor, viral peptide and HLA-A2. Nature. 1996; 384:134–141. [PubMed: 8906788]
6. Burrows SR, Chen Z, Archbold JK, Tynan FE, Beddoe T, Kjer-Nielsen L, Miles JJ, Khanna R,
Moss DJ, Liu YC, Gras S, Kostenko L, Brennan RM, Clements CS, Brooks AG, Purcell AW,
McCluskey J, Rossjohn J. Hard wiring of T cell receptor specificity for the major histocompatibility
complex is underpinned by TCR adaptability. Proc. Natl Acad. Sci. USA. 2010; 107:10608–10613.
[PubMed: 20483993]
7. Manning TC, Schlueter CJ, Brodnicki TC, Parke EA, Speir JA, Garcia KC, Teyton L, Wilson IA,
Kranz DM. Alanine scanning mutagenesis of an alphabeta T cell receptor: mapping the energy of
antigen recognition. Immunity. 1998; 8:413–425. [PubMed: 9586632]
8. Sim BC, Zerva L, Greene MI, Gascoigne NR. Control of MHC restriction by TCR Valpha CDR1
and CDR2. Science. 1996; 273:963–966. [PubMed: 8688082]
9. Wu LC, Tuot DS, Lyons DS, Garcia KC, Davis MM. Two-step binding mechanism for T-cell
receptor recognition of peptide MHC. Nature. 2002; 418:552–556. [PubMed: 12152083]
10. Feng D, Bond CJ, Ely LK, Maynard J, Garcia KC. Structural evidence for a germline-encoded T
cell receptor-major histocompatibility complex interaction 'codon'. Nature Immunol. 2007; 8:975–
983. [PubMed: 17694060]
11. Huseby ES, Crawford F, White J, Marrack P, Kappler JW. Interface-disrupting amino acids
establish specificity between T cell receptors and complexes of major histocompatibility complex
and peptide. Nature Immunol. 2006; 7:1191–1199. [PubMed: 17041605]
12. Scott-Browne JP, White J, Kappler JW, Gapin L, Marrack P. Germline-encoded amino acids in the
alphabeta T-cell receptor control thymic selection. Nature. 2009; 458:1043–1046. [PubMed:
19262510]
13. Holland SJ, Bartok I, Attaf M, Genolet R, Luescher IF, Kotsiou E, Richard A, Wang E, White M,
Coe DJ, Chai JG, Ferreira C, Dyson J. The T-cell receptor is not hardwired to engage MHC
ligands. Proc. Natl Acad. Sci. USA. 2012; 109:E3111–E3118. [PubMed: 23077253]
14. Deng L, Langley RJ, Wang Q, Topalian SL, Mariuzza RA. Structural insights into the editing of
germ-line-encoded interactions between T-cell receptor and MHC class II by V CDR3. Proc. Natl
Acad. Sci. USA. 2012; 109:14960–14965. [PubMed: 22930819]
Smith et al. Page 11













15. Lee PU, Churchill HR, Daniels M, Jameson SC, Kranz DM. Role of 2CT cell receptor residues in
the binding of self- and allo-major histocompatibility complexes. J. Exp. Med. 2000; 191:1355–
1364. [PubMed: 10770802]
16. Colf LA, Bankovich AJ, Hanick NA, Bowerman NA, Jones LL, Kranz DM, Christopher Garcia K.
How a single T cell receptor recognizes both self and foreign MHC. Cell. 2007; 129:135–146.
[PubMed: 17418792]
17. Jones LL, Colf LA, Stone JD, Christopher Garcia K, Kranz DM. Distinct CDR3 conformations in
TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation.
J. Immunol. 2008; 181:6255–6264. [PubMed: 18941216]
18. Chervin AS, Stone JD, Soto CM, Engels B, Schreiber H, Roy EJ, Kranz DM. Design of T-cell
receptor libraries with diverse binding properties to examine adoptive T-cell responses. Gene Ther.
2012
19. Aggen DH, Chervin AS, Insaidoo FK, Piepenbrink KH, Baker BM, Kranz DM. Identification and
engineering of human variable regions that allow expression of stable single-chain T cell
receptors. Protein Eng. Des. Sel. 2011; 24:361–372. [PubMed: 21159619]
20. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-
Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N,
Dietrich P-Y, Speiser DE, Cerottini J-C. Antigenicity and immunogenicity of Melan-A/MART-1
derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 2002;
188:81–96. [PubMed: 12445283]
21. Cole DK, Sami M, Scott DR, Rizkallah PJ, Borbulevych OY, Todorov PT, Moysey RK, Jakobsen
BK, Boulter JM, Baker BM, Yi L. Increased Peptide Contacts Govern High Affinity Binding of a
Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Front. Immunol. 2013; 4:168.
[PubMed: 23805144]
22. Shusta EV, Holler PD, Kieke MC, Kranz DM, Wittrup KD. Directed evolution of a stable scaffold
for T-cell receptor engineering. Nat. Biotechnol. 2000; 18:754–759. [PubMed: 10888844]
23. Weber KS, Donermeyer DL, Allen PM, Kranz DM. Class II-restricted T cell receptor engineered
in vitro for higher affinity retains peptide specificity and function. Proc. Natl Acad. Sci. USA.
2005; 102:19033–19038. [PubMed: 16365315]
24. Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F,
Cerottini JC, Romero P. Diversity of the fine specificity displayed by HLA-A*0201-restricted
CTL specific for the immunodominant Melan- A/MART-1 antigenic peptide. J. Immunol. 1998;
161:6956–6962. [PubMed: 9862730]
25. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F,
Cerottini JC, Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected
Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 1998; 160:1750–1758.
[PubMed: 9469433]
26. Valmori D, Lévy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Liénard D, Cerundolo V,
Cerottini JC, Romero P. Induction of potent antitumor CTL responses by recombinant vaccinia
encoding a melan-A peptide analogue. J. Immunol. 2000; 164:1125–1131. [PubMed: 10623865]
27. Rivoltini L, Squarcina P, Loftus DJ, Castelli C, Tarsini P, Mazzocchi A, Rini F, Viggiano V, Belli
F, Parmiani G. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma
CD8+ T cells with enhanced functional characteristics: implication for more effective
immunotherapy. Cancer Res. 1999; 59:301–306. [PubMed: 9927036]
28. Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ. Recurrence
of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect
killing aided by high levels of tumor antigen cross-presented on stromal cells. J. Immunol. 2009;
183:1828–1837. [PubMed: 19592642]
29. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily conserved amino acids
that control TCR-MHC interaction. Annu. Rev. Immunol. 2008; 26:171–203. [PubMed:
18304006]
30. Hawse WF, Champion MM, Joyce MV, Hellman LM, Hossain M, Ryan V, Pierce BG, Weng Z,
Baker BM. Cutting Edge: Evidence for a Dynamically Driven T Cell Signaling Mechanism. J.
Immunol. 2012; 188:5819–5823. [PubMed: 22611242]
Smith et al. Page 12













31. Haidar JN, Pierce B, Yu Y, Tong W, Li M, Weng Z. Structure-based design of a T-cell receptor
leads to nearly 100-fold improvement in binding affinity for pepMHC. Proteins. 2009; 74:948–
960. [PubMed: 18767161]
32. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR,
Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, Wittrup KD. Flow-cytometric isolation of
human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat.
Biotechnol. 2003; 21:163–170. [PubMed: 12536217]
33. Piepenbrink KH, Blevins SJ, Scott DR, Baker BM. The basis for limited specificity and MHC
restriction in a T cell receptor interface. Nat. Commun. 2013; 4:1948. [PubMed: 23736024]
34. Borg NA, Ely LK, Beddoe T, Macdonald WA, Reid HH, Clements CS, Purcell AW, Kjer-Nielsen
L, Miles JJ, Burrows SR, McCluskey J, Rossjohn J. The CDR3 regions of an immunodominant T
cell receptor dictate the 'energetic landscape' of peptide-MHC recognition. Nature Immunol. 2005;
6:171–180. [PubMed: 15640805]
35. Scott-Browne JP, Matsuda JL, Mallevaey T, White J, Borg NA, McCluskey J, Rossjohn J, Kappler
J, Marrack P, Gapin L. Germline-encoded recognition of diverse glycolipids by natural killer T
cells. Nature Immunol. 2007; 8:1105–1113. [PubMed: 17828267]
36. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-
reactivity. Nature Immunol. 2003; 4:55–62. [PubMed: 12469116]
37. Holler P, Holman P, Shusta E, O&apos;Herrin S, Wittrup K, Kranz D. In vitro evolution of a T cell
receptor with high affinity for peptide/MHC. Proc. Natl Acad. Sci. USA. 2000; 97:5387–5392.
[PubMed: 10779548]
38. Li Y, Moysey R, Molloy PE, Vuidepot A-L, Mahon T, Baston E, Dunn S, Liddy N, Jacob J,
Jakobsen BK, Boulter JM. Directed evolution of human T-cell receptors with picomolar affinities
by phage display. Nat. Biotechnol. 2005; 23:349–354. [PubMed: 15723046]
39. Dunn SM, Rizkallah PJ, Baston E, Mahon T, Cameron B, Moysey R, Gao F, Sami M, Boulter J, Li
Y, Jakobsen BK. Directed evolution of human T cell receptor CDR2 residues by phage display
dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-
reactivity. Protein Sci. 2006; 15:710–721. [PubMed: 16600963]
40. Chlewicki LK, Holler PD, Monti BC, Clutter MR, Kranz DM. High-affinity, peptide-specific T
cell receptors can be generated by mutations in CDR1, CDR2 or CDR3. J. Mol. Biol. 2005;
346:223–239. [PubMed: 15663940]
41. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T,
Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE,
June CH, Jakobsen BK, Sewell AK, Riley JL. Control of HIV-1 immune escape by CD8 T cells
expressing enhanced T-cell receptor. Nat. Med. 2008; 14:1390–1395. [PubMed: 18997777]
42. Manning TC, Kranz DM. Binding energetics of T-cell receptors: correlation with immunological
consequences. Immunol. Today. 1999; 20:417–422. [PubMed: 10462742]
43. Sykulev Y, Brunmark A, Jackson M, Cohen RJ, Peterson PA, Eisen HN. Kinetics and affinity of
reactions between an antigen-specific T cell receptor and peptide-MHC complexes. Immunity.
1994; 1:15–22. [PubMed: 7889394]
44. Bowerman NA, Crofts TS, Chlewicki L, Do P, Baker BM, Christopher Garcia K, Kranz DM.
Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that
governs T cell activity. Mol. Immunol. 2009; 46:3000–3008. [PubMed: 19595460]
45. Baker BM, Scott DR, Blevins SJ, Hawse WF. Structural and dynamic control of T-cell receptor
specificity, cross-reactivity, and binding mechanism. Immunological reviews. 2012; 250:10–31.
[PubMed: 23046120]
46. Ding YH, Baker BM, Garboczi DN, Biddison WE, Wiley DC. Four A6-TCR/peptide/HLA-A2
structures that generate very different T cell signals are nearly identical. Immunity. 1999; 11:45–
56. [PubMed: 10435578]
47. Gagnon SJ, Borbulevych OY, Davis-Harrison RL, Turner RV, Damirjian M, Wojnarowicz A,
Biddison WE, Baker BM. T cell receptor recognition via cooperative conformational plasticity. J.
Mol. Biol. 2006; 363:228–243. [PubMed: 16962135]
Smith et al. Page 13













48. Scott DR, Borbulevych OY, Piepenbrink KH, Corcelli SA, Baker BM. Disparate degrees of
hypervariable loop flexibility control T-cell receptor cross-reactivity, specificity, and binding
mechanism. J. Mol. Biol. 2011; 414:385–400. [PubMed: 22019736]
49. Rodenko B, Toebes M, Hadrup SR, Van Esch WJE, Molenaar AM, Schumacher TNM, Ovaa H.
Generation of peptide–MHC class I complexes through UV-mediated ligand exchange. Nat.
Protoc. 2006; 1:1120–1132. [PubMed: 17406393]
50. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, Van De Kasteele W,
Rimmelzwaan GF, Haanen JBAG, Ovaa H, Schumacher TNM. Design and use of conditional
MHC class I ligands. Nat. Med. 2006; 12:246–251. [PubMed: 16462803]
51. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent
femtomolar antigen-binding affinity. Proc. Natl Acad. Sci. USA. 2000; 97:10701–10705.
[PubMed: 10984501]
52. Fleischer K, Schmidt B, Kastenmüller W, Busch DH, Drexler I, Sutter G, Heike M, Peschel C,
Bernhard H. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by
dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with
melanoma-derived heat shock proteins in vitro. J. Immunol. 2004; 172:162–169. [PubMed:
14688322]
53. Hoo W, Lacy M, Denzin L, Voss E, Hardman K, Kranz D. Characterization of a single-chain T-
cell receptor expressed in Escherichia coli. Proc. Natl Acad. Sci. USA. 1992; 89:4759–4763.
[PubMed: 1584815]
54. Richman SA, Kranz DM, Stone JD. Biosensor detection systems: engineering stable, high-affinity
bioreceptors by yeast surface display. Methods Mol. Biol. 2009; 504:323–350. [PubMed:
19159105]
55. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap
extension using the polymerase chain reaction. Gene. 1989; 77:51–59. [PubMed: 2744487]
56. Garcia KC, Radu CG, Ho J, Ober RJ, Ward ES. Kinetics and thermodynamics of T cell receptor-
autoantigen interactions in murine experimental autoimmune encephalomyelitis. Proc. Natl Acad.
Sci. USA. 2001; 98:6818–6823. [PubMed: 11391002]
57. Davis-Harrison RL, Armstrong KM, Baker BM. Two different T cell receptors use different
thermodynamic strategies to recognize the same peptide/MHC ligand. J. Mol. Biol. 2005;
346:533–550. [PubMed: 15670602]
58. Karlsson R, Katsamba PS, Nordin H, Pol E, Myszka DG. Analyzing a kinetic titration series using
affinity biosensors. Anal. Biochem. 2006; 349:136–147. [PubMed: 16337141]
Smith et al. Page 14














• Several key residues of the TCR have been proposed to account for MHC-
restriction
• Yeast display enabled engineering of high-affinity TCR against antigen
MART-1
• Binding analysis of several TCRs revealed energetic importance of CDR2α
residue Y51
• Plasticity in binding was observed for other CDR1α & CDR2α residues
• Evolutionary pressure for wild-type residues at key MART1 single-chain TCR
residues
• Residue Y51 could contribute significantly to positive selection of all of the
TCRs
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Figure 1. Yeast display and isolation of INR1-T1 (T1) single-chain TCR variable fragments
(scTv)
(a) Schematic of scTv fusions for the human TCR, T1, which recognizes MART-1 peptides
in presented in the context of HLA-A2. (b) The T1 TCR was cloned as a scTv and expressed
on the surface of yeast (left panels). Yeast surface of scTV fusions were monitored for
expression of an N-terminal tag [hemagluttanin (HA), black line] with anti-HA antibody and
goat anti-mouse IgG alexa 647 secondary antibody or secondary only as a control (gray).
The negative peak is is due to yeast that have lost plasmid, and serves as an internal control
for each induced yeast sample. Cells were incubated with anti-Vβ16 and anti-Vα2 antibodies
followed by goat anti-mouse IgG alexa 647 secondary antibody, or secondary only as a
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control (gray). Cells were incubated with MART-1 peptide (ELAGIGILT)/HLA-A2 dimer
at 100 nM. A random mutagenesis library was generated using the T1 scTv as a template
and sorted with anti-Vβ16 antibody and goat anti-mouse IgG alexa 647 secondary antibody.
Clone T1-S18 was isolated after two rounds of sorting (middle panels). Site directed
libraries were made in CDR3 loop regions of the stabilized T1-S18 clone. The high affinity
clone, T1-S18.45, was isolated following 4 rounds of sorting with MART-1 peptide
(ELAGIGILT)/HLA-A2 dimer (right panels, black line). Histograms are representative of 3
or more experiments.
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Figure 2. Purity and surface plasmon resonance of soluble MART-1-specific, single-chain TCR
T1 and its engineered variants
T1 wt, T1-S18, and T1-S18.45 were expressed in the E.coli pET28 expression system,
refolded from inclusion bodies, and purified by Ni-column and size exclusion
chromatography. (a) SDS-PAGE of purified scTvs and molecular weight markers (M). (b)
SPR trace of MART-1 (ELAGIGILTV)/HLA-A2 binding immobilized T1-S18.45. Fitted
parameters (KD, kon, koff) are shown in the inset. (c) Table showing the binding affinities of
the T1-derived TCRs for variants of the MART-1 peptide.
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Figure 3. Binding of peptide-loaded antigen presenting cells by soluble T1-S18.45 scTv
(a) Titration of biotinylated T1-S18.45 scTv on antigen-presenting cell line T2 (HLA-A2+)
preloaded with MART-1 peptide (1 µM) or null peptide, SL9 (1 µM). Cells were stained
with 3.9 nM (tan), 7.8 nM (gray), 15.2 nM (red), 31.1 nM (purple), 62.5 nM (green), 250
nM (blue), or 1 µM (black) biotinylated T1-S18.45 scTv, followed by SA:PE. Data shown is
representative of 4 experiments. (b) Mean fluorescence unit (MFU) values of histograms in
(a) are plotted versus scTv-biotin concentration.
Smith et al. Page 19













Figure 4. Crystal structures of Vα2-containing TCRs showing MHC contact positions in CDR1α
and CDR2α loops
CDR1α residues D27, R28, and Q31 (a,c,e), and CDR2α residues Y51 and S52 (b,d,f)
assessed in the alanine scanning study are highlighted in the structures of the A6 (a,b)5,
Mel5 (c,d)4, and DMF5 (e,f)3 TCRs, which all contain the Vα2 region. PDB files 1AO7,
3HG1, and 3QDG were used, respectively, in PyMol. TCR residue positions are indicated in
black. MHC residues are italicized in gray.
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Figure 5. Alanine scanning mutagenesis of Vα2-containing single-chain TCRs
Binding titrations of yeast-displayed mutants of Vα2-containing single-chain TCR
fragments (scTv): (a), A6-X15 specific for Tax/HLA-A2, (b) 868 Z11 specific for SL9/
HLA-A2, and (c) T1-S18.45 specific for MART-1/HLA-A2. Alanine mutants were stained
in triplicate with 8 nM, 40 nM, 200 nM, 1 µM, and 5 µM cognate peptide/HLA-A2
monomers followed by PE-conjugated streptavidin. Normalized percent max mean
fluorescence intensity (MFI) is plotted against cognate peptide/HLA-A2 monomer
concentration. Error bars represent standard deviations of triplicate experiments. (d) Fold
changes in binding were determined by the scTv concentrations at one-half max wild-type
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binding from titrations in Figure 4a,b,c. Error bars represent standard deviations of triplicate
experiments.
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Figure 6. In vitro selected mutants of yeast-display libraries of the MART-1-specific TCR (T1-
S18.45)
Yeast display libraries at position 31 in CDR1α (a) and position 51 in CDR2α (b) were
generated, stained with 45 nM MART-1 (ELAGIGITV)/HLA-A2, and selected by
fluorescence activated cell sorting. The top staining (8–10%) clones were isolated, and
amino acid distribution was determined by 454 sequencing. Amino acid residues that were
positively and negative selected are indicated on the y-axis as a function of the ratio of the
logarithm of amino acid frequency post-selection divided by the logarithm of the frequency
pre-selection. A total of 11,736 and 13,600 clones from the unselected position 31 library
and selected position 31 library were sequenced, respectively; a total of 6,806, and 24,532
from the unselected position 51 library and selected position 51 library were sequenced,
respectively.
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